AstraZeneca licenses novel antidepressant compounds discovered by Mayo Clinic, Virginia Tech collaboration
Files
TR Number
Date
2009-02-09
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Virginia Tech. University Relations
Abstract
AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.
Description
Keywords
Research